Publications by authors named "J B Auliac"
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Lung Cancer
November 2024
Background: BRAF V600E mutations occur in 2-5 % of advanced non-small cell lung cancer (NSCLC) patients. The dabrafenib-trametinib (D-T) combination was associated with improved and durable OS in patients in phase II. This study (IFCT-2004 BLaDE study) reported the efficacy of D-T combination in a large retrospective French real-world multicenter cohort of patients with advanced BRAF V600E-mutated NSCLC.
View Article and Find Full Text PDFBackground: Use of immune checkpoint inhibitors (ICIs) is associated with new response types, such as hyperprogressive disease (HPD), whose definition is still being discussed. Some authors use dynamic indexes to define HPD. However, since the Checkmate-743 study, ICIs have been a first-line therapy for pleural mesothelioma (PM), thereby making use of dynamic indexes less appropriate.
View Article and Find Full Text PDFArticle Synopsis
- Osimertinib is a first-line treatment for patients with mutation-positive non-small cell lung cancer (NSCLC), but resistance often develops due to mutations like L718Q or G724S after treatment.
- This study retrospectively examined nine NSCLC patients in France who acquired these rare mutations after initial EGFR TKI therapy, noting their tumor characteristics and treatment progression.
- Although no standard treatment exists after these mutations occur, afatinib showed potential effectiveness, with some patients achieving partial responses and others remaining stable for several months.
Article Synopsis
- A tyrosine-kinase inhibitor (TKI) is recommended as the primary treatment for non-small-cell lung cancer (NSCLC) patients with an epidermal growth-factor receptor mutation, and the effectiveness of combining it with chemotherapy (ChT) is being researched.
- A meta-analysis of four phase III trials involving 1,413 NSCLC patients indicated that the combination of EGFR-TKI and ChT resulted in significantly longer progression-free survival (PFS) and overall survival (OS) compared to EGFR-TKI alone.
- The combination treatment showed especially improved PFS for patients with brain metastases, but more research is necessary to determine which patients are most likely to benefit from this combined approach.
Article Synopsis
- The study evaluated the management practices for stage III non-small-cell lung cancer (NSCLC) across 41 medical centers in France between 2020 and 2022, focusing on diagnostic and treatment methods.
- Results indicated that standard imaging techniques were widely used, but invasive staging procedures were underperformed despite a high incidence of node involvement.
- The findings showed that treatment generally adhered to clinical guidelines, though a notable gap in the frequency of invasive staging was identified.